Bitget releases February transparency report, bitcoin reserves see 86% annual growth
Foresight News reported that Bitget has released its Transparency Report for February 2026. In terms of product and technological innovation, Bitget has further upgraded its AI trading infrastructure and launched Agent Hub. Recently, Agent Hub has added two major modules: Skills and CLI, which, together with MCP and REST/WebSocket API, form a complete invocation system of "MCP + API + Skills + CLI," bridging the connection between AI models, development tools, and live trading execution.
According to DefiLlama data, in February 2026, Bitget ranked third globally among centralized exchanges in terms of capital inflow. Meanwhile, CryptoQuant data shows that Bitget's bitcoin reserves increased from approximately 19,700 BTC at the beginning of 2025 to about 36,700 BTC in February 2026, representing a year-on-year growth of 86%.
In addition, Bitget has comprehensively upgraded its mobile app, adding a dedicated TradFi section on the homepage, where crypto assets are displayed alongside products related to stocks, forex, indices, commodities, and precious metals. After the upgrade, the overall operation process is reduced by about 30% compared to the industry standard, further advancing the panoramic exchange UEX strategic vision.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
